Helio Genomics CEO Bharat Tewarie joined David Filby on the Diagnosing Dx podcast to talk about a gap that doesn’t get enough attention: too many high-risk patients slip through the cracks in liver cancer surveillance because it still leans so heavily on ultrasound.
In the conversation, Bharat looks at where imaging falls short, how AI-powered multiomics and HelioLiver could help catch liver cancer earlier from a simple blood draw, and why early detection only makes a difference if patients can actually access it. Drawing on decades of leadership across pharma, biotech, diagnostics, and digital health, he also shares how Helio is thinking about physician adoption, workflow, and the partnerships needed to turn strong science into real clinical impact.
What the episode covers
- Why liver cancer surveillance still leaves many high-risk patients undetected
- How AI-powered multiomics and HelioLiver could improve early detection
- Why access and workflow matter as much as test performance
- How partnerships can speed up commercialization and patient reach
- What Helio is building beyond HelioLiver as it expands its platform
Related: AI-driven cancer detection
Source: Diagnosing Dx podcast, hosted by Elevra Consulting. Listen to the full episode.